BioSpace News Archive

Through its leading imaging solutions and commitment to innovation, GE HealthCare remains at the forefront of leveraging deep learning, a subset of artificial intelligence, to benefit a multitude of clinicians and patients.

PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) (“PureTech” or the “Company”) noted today that its Founded Entity, Karuna Therapeutics, Inc. (Nasdaq: KRTX) (“Karuna”) announced the U.S. Food and Drug Administration (FDA) has accepted its New Drug Application (NDA) for KarXT (xanomeline-trospium) for the treatment of schizophrenia in adults.

Britannia Life Sciences Inc. (CSE: BLAB) (FSE: L020) (“Britannia” or the “Company”) is pleased to provide its unaudited financial results for the three- and six- month periods ended September 30, 2023. These filings and additional information regarding Britannia are available for review on SEDAR at www.sedar.com. All amounts are Canadian dollars unless otherwise stated.

Nalu Medical, Inc (“Nalu”) is a Carlsbad, California-based company that has successfully miniaturized neurostimulation implants for the management of chronic intractable pain across a variety of targets with both spinal cord stimulation (SCS) and peripheral nerve stimulation (PNS) indications.

The shareholders of Promore Pharma AB, reg. no. 556639-6809, are hereby invited to an extraordinary general meeting on 29 December 2023 at 10:00 am CET at Eversheds Sutherland’s premises at Sveavägen 20, 111 57 Stockholm.

Ocean Biomedical, Inc., announced that on November 22, 2023, it received a notice from The Nasdaq Stock Market LLC stating that because the Company has not yet filed its quarterly report on Form 10-Q for the period ended September 30, 2023, the Company is not in compliance with Nasdaq Listing Rule 5250, which requires listed companies to timely file all required periodic reports with the Securities and Exchange Commission.

Atara Biotherapeutics, Inc. (Nasdaq: ATRA) today announced positive new data for tabelecleucel (tab-cel® or EBVALLO™) in patients with relapsed or refractory (r/r) or treatment-naïve Epstein-Barr virus-positive post-transplant lymphoproliferative disease involving the central nervous system (CNS) (EBV+ CNS PTLD) following solid organ transplant (SOT) or hematopoietic cell transplant (HCT).

Everest Medicines announced that its New Drug Application for Nefecon® has been accepted for review by South Korean’s Ministry of Food and Drug Safety for the treatment of primary immunoglobulin A nephropathy in adult patients.

Plus Therapeutics, Inc. today announced that Marc H. Hedrick, M.D., President and Chief Executive Officer, will deliver a presentation at the 5th Targeted Radiopharmaceuticals Summit Europe, being held December 5-7, 2023 in Berlin, Germany.

Gain Therapeutics, Inc. today announced that Matthias Alder, Chief Executive Officer, will participate on a panel during the AI Driven Drug Discovery Summit taking place at the Sheraton Boston Hotel, in Boston, Massachusetts December 5-6, 2023.